Apotex Inc. v. Pfizer Canada Inc., 2019 FCA 16
| Court | Federal Court of Appeal (Canada) |
| Case Date | January 25, 2019 |
| Jurisdiction | Canada (Federal) |
| Citations | 2019 FCA 16 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
24 practice notes
-
Angelcare Canada Inc. v. Munchkin, Inc., 2022 FC 507
...Easton Sports Canada Inc., 2010 FC 361 at para. 250, aff’d 2011 FCA 83; Pfizer Canada Inc. v. Apotex Inc., 2017 FC 774 at para. 247, aff’d 2019 FCA 16 (Pfizer Canada Inc.)). [Emphasis added.] [369] Justice Rennie goes on at paragraphs 75 to 77 to explain how identifying the inventive concep......
-
Takeda Canada Inc. v. Apotex Inc., 2024 FC 106
...at para 63; Atazanavir at para 61. The analysis is to be flexible, contextual, expansive and fact-driven (Apotex Inc v Pfizer Canada Inc, 2019 FCA 16 at para 39) and is to be undertaken on a claim-by-claim basis (Apotex Inc v Shire LLC, 2021 FCA 52 at paras 26 and 55 (2) PSA and CGK [183]......
-
Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC, 2020 FC 816
...called properties of the invention, benefits of the invention, or results of the invention (BMS FCA at para 74; Apotex v Pfizer 2019 FCA 16 para 37–45; Hospira FCA at para 94; the 684 Patent NOC decision at para 164). There is no need to look to the disclosure for improved properties, if a ......
-
Eli Lilly Canada Inc. v. Apotex Inc., 2020 FC 814
...the inventiveness analysis, and cite Teva Canada Limted v Pfizer Canada Inc, 2019 FCA 15 at para 35 and Apotex Inc v Pfizer Canada Inc, 2019 FCA 16 at para 39. [252] Lilly argue that, under the obviousness analysis, the subject-matter defined by a claim, ie the inventive concept, must be ......
Request a trial to view additional results
15 cases
-
Angelcare Canada Inc. v. Munchkin, Inc., 2022 FC 507
...Easton Sports Canada Inc., 2010 FC 361 at para. 250, aff’d 2011 FCA 83; Pfizer Canada Inc. v. Apotex Inc., 2017 FC 774 at para. 247, aff’d 2019 FCA 16 (Pfizer Canada Inc.)). [Emphasis added.] [369] Justice Rennie goes on at paragraphs 75 to 77 to explain how identifying the inventive concep......
-
Takeda Canada Inc. v. Apotex Inc., 2024 FC 106
...at para 63; Atazanavir at para 61. The analysis is to be flexible, contextual, expansive and fact-driven (Apotex Inc v Pfizer Canada Inc, 2019 FCA 16 at para 39) and is to be undertaken on a claim-by-claim basis (Apotex Inc v Shire LLC, 2021 FCA 52 at paras 26 and 55 (2) PSA and CGK [183]......
-
Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC, 2020 FC 816
...called properties of the invention, benefits of the invention, or results of the invention (BMS FCA at para 74; Apotex v Pfizer 2019 FCA 16 para 37–45; Hospira FCA at para 94; the 684 Patent NOC decision at para 164). There is no need to look to the disclosure for improved properties, if a ......
-
Eli Lilly Canada Inc. v. Apotex Inc., 2020 FC 814
...the inventiveness analysis, and cite Teva Canada Limted v Pfizer Canada Inc, 2019 FCA 15 at para 35 and Apotex Inc v Pfizer Canada Inc, 2019 FCA 16 at para 39. [252] Lilly argue that, under the obviousness analysis, the subject-matter defined by a claim, ie the inventive concept, must be ......
Request a trial to view additional results
9 firm's commentaries
-
Form I: Crystal Form Patents In The Federal Court Of Canada ' A Review Of Case Law On Claims Construction And Selection Patents
...100-106. 16 Efaviernze, supra, paras. 107-109. 17 Pfizer Canada Inc. v. Apotex Inc.(2017), 150 CPR (4th) 1 (FC) ("Apo-Venlafaxine"), aff'd 2019 FCA 16. 18 Apo-Venlafaxine, supra, paras. 19 Apo-Venlafaxine, supra, paras. 162-163. 20 Sitagliptin, supra, paras. 112-118 21 Sitagliptin, supra, p......
-
Form II: Anticipation And Obviousness Of Crystal Form Patents In The Federal Court Of Canada
...Inc. v. Teva Canada Ltd., 2017 FC 777 aff'd 2019 FCA 15 ("Desvenlafaxine-Teva") and Pfizer Canada Inc. v. Apotex Inc., 2017 FC 774 aff'd 2019 FCA 16 ("Desvenlafaxine-Apotex"), collectively, 9. FC Desvenlafaxine-Teva supra at para. 27. 10. FC Desvenlafaxine-Teva supra at para. 32. 11. FC Des......
-
Orders of prohibition relating to polymorphic form patent for PRISTIQ upheld on appeal
...both Apotex’s and Teva’s appeals: Teva v Pfizer, 2019 FCA 15; Apotex v Pfizer, 2019 FCA 16. The 668 Patent relates to a novel crystal form of a particular salt of ODV: Form I ODV succinate. Obviousness was the only issue in the Teva appeal. Obviousness and anticipation were at issue in the ......
-
FCA Confirms Entirety Of Inventors' Conduct Is Relevant In Obviousness Analysis And Upholds Inventiveness Of Crystal Form Patent
...for his help on this post. Link: Teva Canada Ltd. v. Pfizer Canada Inc. et al., 2019 FCA 15; Apotex Inc. v. Pfizer Canada Inc. et al., 2019 FCA 16. About Norton Rose Fulbright Canada Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial ins......
Request a trial to view additional results